A new review finds only 7.3% of segmental vitiligo patients regain pigmentation with standard therapy, pointing to a distinct biological mechanism that current treatments largely miss.
One number from a review in the Journal of Investigative Dermatology lands quietly but firmly: 7.3%. That is the share of segmental vitiligo patients who achieve repigmentation through topical immunomodulation or phototherapy — the treatments most widely offered.
Shen et al. reviewed the pathogenesis and clinical profile of segmental vitiligo as a condition distinct from other forms of the disease. Their review found that segmental vitiligo tends to appear on one side of the body only, shows a preference for the face and skull, and typically stabilises within one to two years of onset. Leukotrichia — the whitening of hair within or near the affected area — is common, the authors reported. Unlike non-segmental vitiligo, this form is associated with low levels of systemic autoimmunity.
A different mechanism, a different challenge
The biology that drives segmental vitiligo is not simply a milder or localised version of what drives other forms, according to the review. Shen et al. identified four overlapping processes: somatic mosaicism, which shapes where lesions appear; neurovascular dysfunction, which amplifies local immune activity; autoimmune destruction of melanocytes; and a particular vulnerability to oxidative stress. Each of these, the authors suggested, plays a role in why the condition behaves the way it does — and why existing therapies so rarely reverse it.
For readers in the albinism community, the distinction matters. Melanocyte function — and its disruption — sits at the centre of both albinism and vitiligo research, even as the underlying mechanisms differ. Work that clarifies why melanocytes are destroyed in one condition, and why they resist restoration, feeds a broader understanding of pigmentation biology and the limits of current dermatological tools.
The review frames the low repigmentation rate not as a treatment failure in individual cases, but as a signal that the disease mechanism itself is not yet well enough understood to be adequately targeted. Improved therapies, Shen et al. argued, depend on closer attention to that mechanism.
The paper was published in the Journal of Investigative Dermatology.
Keywords
Core topics and entities mentioned in this summary.